Last reviewed · How we verify

Prevacid — Competitive Intelligence Brief

Prevacid (Prevacid) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Pain.

marketed ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase Pain Small molecule Live · refreshed every 30 min

Target snapshot

Prevacid (Prevacid) — Vanderbilt University Medical Center.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Prevacid TARGET Prevacid Vanderbilt University Medical Center marketed ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase
Prevacid lansoprazole Generic (originally Takeda) marketed Proton pump inhibitor (PPI) ATP-binding cassette sub-family G member 2, Cytochrome P450 2C19, Cytosolic endo-beta-N-acetylglucosaminidase 1995-05-10

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Prevacid — Competitive Intelligence Brief. https://druglandscape.com/ci/prevacid. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: